Reliable Anticoagulation with Enoxaparin in Patients Undergoing Percutaneous Coronary Intervention: The Pharmacokinetics of Enoxaparin in PCI (PEPCI) Study

Catheterization and Cardiovascular Interventions

Volumn 61, Issue 2, 2004, Pages 163-170

  Martin, Jack L ^a   Fry, Edward T A ^b   Sanderink, Ger Jan C M ^c   Atherley, Trevor H ^d   Guimart, Colette M ^c   Chevalier, Paul J ^c   Ozoux, Marie Laure ^c   Pensyl, Catherine E ^a   Bigonzi, Frederique ^c  

^a BRYN MAWR HOSPITAL   (United States)

^b ST VINCENT HOSPITAL   (United States)

^c SANOFI   (France)

^d NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Anticoagulants; Heparins; Myocardial infarction; Unstable angina

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; ENOXAPARIN; EPTIFIBATIDE; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN A; TIROFIBAN;

ADULT; AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD SAMPLING; BOLUS INJECTION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART CATHETERIZATION; HUMAN; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PERCUTANEOUS CORONARY INTERVENTION;

ADOLESCENT; ADULT; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; CORONARY ANGIOGRAPHY; ENOXAPARIN; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES;

EID: 0742270477     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.10726     Document Type: Article

References (16)

1. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease: efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group. N Engl J Med 1997;337:447-452.
2. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction; Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation 1999;100:1593-1601.
3. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis. Circulation 1999;100:1602-1608.
4. Montalescot G, Collet JP, Lison L, et al. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 2000;36:110-114.
5. Brace LD, Fareed J, Tomeo J, Issleib S. Biochemical and pharmacological studies on the interaction of PK 10169 and its subfractions with human platelets. Haemostasis 1986;16:93-105.
6. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-1887.
7. FRISC investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999;354:708-715.
8. Kereiakes DJ, Grines C, Fry E, et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invas Cardiol 2001;13:272-278.
9. Choussat R, Montalescot G, Collet JP, et al. A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol 2002;40:1943-1950.
10. Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001;103:658-663.
11. Thrombolysis in Myocardial Infarction (TIMI) 11A trial investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. J Am Coll Cardiol 1997;29:1474-1482.
12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
13. EPILOG investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
14. Chew DP, Bhatt DL, Lincoff AM, et al. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation 2001;103:961-966.
15. Smith SC Jr, Dove JT, Jacobs AK, et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines): executive summary-a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol 2001;37:2215-2239.
16. SYNERGY executive committee. Superior yield of the new strategy of enoxaparin, revascularization and glycoprotein iib/iiia inhibitors: the SYNERGY trial-study design and rationale. Am Heart J 2002;143:952-960.